November 22nd 2023
Faith E. Davies, MD, discusses strategies for rectifying global gaps and addressing unmet needs in multiple myeloma care.
October 3rd 2023
Faith E. Davies, MD, discusses challenges experienced by hematologist-oncologists and specialist nurses when treating patients with multiple myeloma.
September 25th 2023
Closing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.
Continuing its discussion on clinical trials in multiple myeloma, the panel emphasizes the impact that data may have on the real-world treatment landscape.
September 18th 2023
Key opinion leaders in multiple myeloma management elucidate the value of clinical trials and share enthusiasm for improving enrollment when possible.
A focused discussion on the regulatory aspects of drug testing and approval, globally, with respect to the setting of multiple myeloma management.
September 11th 2023
Expert panelists consider best methods in educating patients on their options for therapy following a diagnosis of multiple myeloma.
Comprehensive insight to disparities that may impact a patient’s access to therapy for multiple myeloma and how these may be overcome.
September 4th 2023
Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma.
Experts in multiple myeloma management consider essential tests that aid in the diagnosis and treatment of newly presenting patients.
August 21st 2023
Shared insight from key opinion leaders on educational resources made available to physicians and patients, respectively, regarding multiple myeloma management.
Opening its discussion on key unmet needs in multiple myeloma management, a panel of experts discuss key challenges faced when diagnosing patients with multiple myeloma and review the impact of having a multidisciplinary care team.
July 6th 2021
Faith Davies, MD, discusses the approval of isatuximab-irfc-based combinations for patients with relapsed/refractory multiple myeloma.
July 1st 2021
Faith E. Davies, MD, discusses the next steps for CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.
June 16th 2021
Faith Davies, MD, discusses future research directions with isatuximab in the treatment of patients with multiple myeloma.
June 3rd 2021
Faith Davies, MD, discusses key considerations for developing a treatment strategy for patients with early-relapse multiple myeloma.
June 9th 2020
Faith E. Davies, MD, shares advice on how to best treat patients with relapsed/refractory multiple myeloma.
April 21st 2020
Faith E. Davies, MD, discusses the research being done in patients with multiple myeloma who are refractory to lenalidomide.
April 14th 2020
Faith E. Davies, MD, discusses the dosing of carfilzomib in the treatment of patients with multiple myeloma.
April 13th 2020
Faith E. Davies, MD, discusses the use of venetoclax as a precision medicine approach in patients with relapsed/refractory multiple myeloma.